Clinical Trials Logo

Postprandial Hypoglycemia clinical trials

View clinical trials related to Postprandial Hypoglycemia.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05401578 Recruiting - Clinical trials for Postprandial Hypoglycemia

Canakinumab for the Treatment of Postprandial Hypoglycemia

CanpHy
Start date: April 17, 2023
Phase: Phase 3
Study type: Interventional

The primary objective of this randomized trial is to test whether a treatment with canakinumab is superior to placebo in patients with postprandial hypoglycemia after bariatric surgery, that is if it improves health related quality of life (mentally or physically) or reduces the risk of hypoglycemic events.

NCT ID: NCT05036317 Recruiting - Clinical trials for Postprandial Hypoglycemia

Empagliflozin for the Treatment of Postprandial Hypoglycemia

EmpHy
Start date: March 11, 2022
Phase: Phase 3
Study type: Interventional

This randomized trial is to test whether a treatment with empagliflozin is superior to placebo in patients with postprandial hypoglycemia after bariatric surgery, that is if it improves health related quality of life (mentally or physically) or reduces the risk of hypoglycemic events.

NCT ID: NCT04720859 Recruiting - Clinical trials for Postprandial Hypoglycemia

Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB)

CANA-PHH-RYGB
Start date: January 5, 2018
Phase: N/A
Study type: Interventional

Roux-en-Y gastric bypass (RYGB) is the most common surgical procedure for morbid obesity. However, it can present serious late complications, like postprandial hyperinsulinemic hypoglycemia (PHH). Recent data suggested an increase in intestinal SGLT1 after RYGB. However, there are no data on the inhibition of SLGT1 to prevent PHH in patients with prior RYBG. Objectives: To evaluate in patients that present PHH after RYGB: a) the effect of canagliflozin 300mg on the response to 100g glucose overload (OGTT); b) the pancreatic response after intra-arterial calcium stimulation. Material and methods: Prospective pilot study, including patients with PHH after RYGB, matched by age and gender with healthy controls. Basal OGTT and after 2-weeks of daily 300mg of canagliflozin will be performed. In addition, venous sampling after intra-arterial calcium stimulation of the pancreas will be performed.